CA2515366C - Compositions and methods to modulate immune and inflammatory responses - Google Patents
Compositions and methods to modulate immune and inflammatory responses Download PDFInfo
- Publication number
- CA2515366C CA2515366C CA2515366A CA2515366A CA2515366C CA 2515366 C CA2515366 C CA 2515366C CA 2515366 A CA2515366 A CA 2515366A CA 2515366 A CA2515366 A CA 2515366A CA 2515366 C CA2515366 C CA 2515366C
- Authority
- CA
- Canada
- Prior art keywords
- rtf
- atp
- cells
- expression
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract description 27
- 230000028709 inflammatory response Effects 0.000 title abstract description 20
- 230000028993 immune response Effects 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 title abstract description 8
- 230000006907 apoptotic process Effects 0.000 claims description 25
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims 1
- 102100020745 V-type proton ATPase 116 kDa subunit a 2 Human genes 0.000 abstract description 131
- 108010076429 regeneration and tolerance factor Proteins 0.000 abstract description 129
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000005934 immune activation Effects 0.000 abstract description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 72
- 230000000694 effects Effects 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 37
- 210000002540 macrophage Anatomy 0.000 description 24
- 108091006112 ATPases Proteins 0.000 description 22
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 22
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 230000004913 activation Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 13
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 12
- 102000000033 Purinergic Receptors Human genes 0.000 description 11
- 108010080192 Purinergic Receptors Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000000589 Interleukin-1 Human genes 0.000 description 10
- 108010002352 Interleukin-1 Proteins 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108010047482 ectoATPase Proteins 0.000 description 7
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 108090000672 Annexin A5 Proteins 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 6
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 6
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001461 cytolytic effect Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 101710191936 70 kDa protein Proteins 0.000 description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102100029723 Ectonucleoside triphosphate diphosphohydrolase 2 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000033540 T cell apoptotic process Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 238000006064 ATPase reaction Methods 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 description 1
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000021603 oncosis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF).
Description
SPECIFICATION
TITLE OF THE INVENTION
"COMPOSITIONS AND METHODS TO MODULATE IMMUNE AND
INFLAMMATORY RESPONSES"
BACKGROUND OF THE INVENTION
The inflaminatory process initiates a localized defense against foreign antigens.
The process is characterized by immune activation as well as destruction of nearby tissues secondary to involved release of destructive agents. Iiiitially involved tissue assumes a significant role in provoking the inflammatory response at large (Matzinger, P., Tlae danger inodel: a renewed sense of self. Science, 2002. 296(5566): p.
301-5;
Medzhitov, R. and C.A. Janeway, Jr., Decoding the patterns of self and nonself by the innate im.naune system. Science, 2002. 296(5566): p. 298-300). One of the primary immunogenic mechanisms triggered by the inflammatory response includes the release of ATP into the extracellular space. ATP is liberated from injured tissue itself-as well as from nearby macrophages, neutropliils, platelets and dying cells-following incidents of stress, infection or other forms of tissue insult (Fredholm, B.B., Purines and neutrophil leukocytes. Gen Pharmacol, 1997. 28(3): p. 345-50; Beigi, R., et al., Detectioit. of local ATP release fi om activated platelets using cell surface-attached firefly luciferase. Am J Physiol, 1999. 276(1 Pt 1): p. C267-78; Schwiebert, E.M., ABC
transporter-facilitated ATP conductive transport. Am J Pliysiol, 1999. 276(1 Pt 1): p.
Cl-8; Mizumoto, N., et al., CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in infammation and imrnune responsiveness. Nat Med, 2002. 8(4): p. 358-65; Dubyalc, G.R. and C. el-Moatassiin, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. An7 J
Physiol, 1993.
265(3 Pt 1): p. C577-606; Gordon, J.L., Extracellular ATP: effects, sources and fate.
Biochem J, 1986. 233(2): p. 309-19). Extracellular ATP can then exert a wide variety of effects on surrounding cells, most notably the induction of apoptotic events leading ultimately to cell death in both lymphocytes and macrophages (Di Virgilio, F., The P2Z
purinoceptor: an. intriguing role in - immunity, inflammation and cell death.
Immunol Today, 1995. 16(11): p. 524-8; Gargett, C.E., J.E. Cornish, and J.S. Wiley, ATP, a partial agonist for the P2Z receptor of human lymphocytes. Br J Pharmacol, 1997.
122(5): p. 911-7; Buisman, H.P., et al., Extracellular ATP induces a large nonselective conductance in macrophage plasma membYanes. Proc Natl Acad Sci U S A, 1988.
85(21): p. 7988-92; Ferrari, D., et al., ATP-mediated cytotoxicity in microglial cells.
Neuropharinacology, 1997. 36(9): p. 1295-301; Zheng, L.M., et al., Extracellular ATP
as a trigger for apoptosis or programmed cell death. J Cell Biol, 1991.
112(2): p. 279-88). Diminution of cell integrity then leads to further ATP release, propagating the inflaininatory response and continued tissue destruction. Recent data have shown an attenuated effect of extracellular ATP in the presence of the regeneration and tolerance factor (RTF) protein. The present invention discloses compositions and methods to modulate inflammatory and immune responses by regulating the activities of RTF. RTF
prevents ATP activation of P2Z, thus preventing the cell from undergoing pro-inflammatory activation and apoptosis.
SUMMARY OF THE INVENTION
The present invention is directed to compositions and methods to modulate inflamnzatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). Immune activation can be accomplished by inhibiting the RTF
activity.
In one embodiment, the RTF activity can be inhibited by administering a RTF
antagonist, which can be a small molecule, a peptide, or an antibody or a fragment thereof. Inhibiting the RTF activity may result in cell apotosis, especially cancer cells such as ovarian carcinoma cells.
Inflammatory responses can be inhibited by increasing the level of activity of RTF. In an embodiment, the method of increasing the level of activity of RTF
is by administering an effective amount of RTF or a fragment of RTF. The RTF or its fragment can be isolated or purified from mammalian cells such as the T-lymphocyte, the B-lymphocyte, the macrophage, thyinus, or the fetalplacental tissue.
Alternatively, the RTF can be synthetic or a recombinant RTF.
The present invention is also directed to a method of treating cancer, such as ovarian cancer, by iiihibiting the RTF activity. In one embodiment, the method to inhibit RTF activity is to administer an effective dose of a RTF antagonist.
The present invention is further directed to a method of treating or ameliorating an inflammatory disorder or an autoimmune disorder or one or more symptoms thereof by administering an effective amount of RTF or a fragment of RTF. The RTF or its fragment can be isolated or purified from mammalian cells such as the T-lymphocyte, the B-lymphocyte, the macrophage, thymus, or the fetalplacental tissue.
Altematively, the RTF can be synthetic or a recombinant RTF. The RTF can be formulated with one or more suitable pharmaceutical excipients for administration by parenteral, intramuscular, topical, nasal, puhnonary, or oral route. The formulation can also be in the form of micropariicles or nanoparticles. In an embodiment, the method of treating or ameliorating an inflammatory disorder or an autoimmune disorder or one or more symptoms thereof includes an additional step of administering a TNF-a antagonist, which includes but is not limited to infliximab, etanercept, D2E7, CDP571, CDP870, thalidomide and its analogs, and phosphodiesterase type N inhibitors. .
Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.
BRIEF DESCRIPTION OF THE FIGURES
FIG. I shows the expression of RTF and P2Z on PBMC and macrophages. Flow cytometric analysis of the expression of RTF and P2Z. Dotted line indicates isotype control antibody. Solid line represents either RTF expression (column 1) or expression (column 2). The first row represents unstimulated PBMC. The second, row represents PBMC stimulated for 72 hours with PHA. The third row represents macrophages.
FIG. 2 illustrates that RTF expression is concurrent with P2Z expression on lymphocytes during stimulation. Lymphocytes were stimulated with PHA for 0-72 hours. The expression on RTF and P2Z was measured at time points 0, 24hrs, and 72 hrs as indicated by flow cytometry. The Y axis represent the percent maximal expression of each molecule. The black bars represent RTF expression and the gray bars represent P2Z expression. Error bars represent the standard error of the mean. .
FIG. 3 shows that RTF moves to the surface of the membrane in a 50 kDa form during activation. PBMC were stimulated for 0-72 hours and RTF size was examined by westem blot and RTF location was examined by confocal microscopy. Panel A:
Western Blot: PBMC were stimulated with plate bound CD3 and CD28 and harvested at the time points indicated (in hours), western blotted and probed by 2C1. Row 1 represents proteins of 70 kDa size, and row 2 represents proteins of 50 kDa size. Each lane represents a stimulation time of 0, 18, 48, and 72 hours respectively.
Panel B:
TITLE OF THE INVENTION
"COMPOSITIONS AND METHODS TO MODULATE IMMUNE AND
INFLAMMATORY RESPONSES"
BACKGROUND OF THE INVENTION
The inflaminatory process initiates a localized defense against foreign antigens.
The process is characterized by immune activation as well as destruction of nearby tissues secondary to involved release of destructive agents. Iiiitially involved tissue assumes a significant role in provoking the inflammatory response at large (Matzinger, P., Tlae danger inodel: a renewed sense of self. Science, 2002. 296(5566): p.
301-5;
Medzhitov, R. and C.A. Janeway, Jr., Decoding the patterns of self and nonself by the innate im.naune system. Science, 2002. 296(5566): p. 298-300). One of the primary immunogenic mechanisms triggered by the inflammatory response includes the release of ATP into the extracellular space. ATP is liberated from injured tissue itself-as well as from nearby macrophages, neutropliils, platelets and dying cells-following incidents of stress, infection or other forms of tissue insult (Fredholm, B.B., Purines and neutrophil leukocytes. Gen Pharmacol, 1997. 28(3): p. 345-50; Beigi, R., et al., Detectioit. of local ATP release fi om activated platelets using cell surface-attached firefly luciferase. Am J Physiol, 1999. 276(1 Pt 1): p. C267-78; Schwiebert, E.M., ABC
transporter-facilitated ATP conductive transport. Am J Pliysiol, 1999. 276(1 Pt 1): p.
Cl-8; Mizumoto, N., et al., CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in infammation and imrnune responsiveness. Nat Med, 2002. 8(4): p. 358-65; Dubyalc, G.R. and C. el-Moatassiin, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. An7 J
Physiol, 1993.
265(3 Pt 1): p. C577-606; Gordon, J.L., Extracellular ATP: effects, sources and fate.
Biochem J, 1986. 233(2): p. 309-19). Extracellular ATP can then exert a wide variety of effects on surrounding cells, most notably the induction of apoptotic events leading ultimately to cell death in both lymphocytes and macrophages (Di Virgilio, F., The P2Z
purinoceptor: an. intriguing role in - immunity, inflammation and cell death.
Immunol Today, 1995. 16(11): p. 524-8; Gargett, C.E., J.E. Cornish, and J.S. Wiley, ATP, a partial agonist for the P2Z receptor of human lymphocytes. Br J Pharmacol, 1997.
122(5): p. 911-7; Buisman, H.P., et al., Extracellular ATP induces a large nonselective conductance in macrophage plasma membYanes. Proc Natl Acad Sci U S A, 1988.
85(21): p. 7988-92; Ferrari, D., et al., ATP-mediated cytotoxicity in microglial cells.
Neuropharinacology, 1997. 36(9): p. 1295-301; Zheng, L.M., et al., Extracellular ATP
as a trigger for apoptosis or programmed cell death. J Cell Biol, 1991.
112(2): p. 279-88). Diminution of cell integrity then leads to further ATP release, propagating the inflaininatory response and continued tissue destruction. Recent data have shown an attenuated effect of extracellular ATP in the presence of the regeneration and tolerance factor (RTF) protein. The present invention discloses compositions and methods to modulate inflammatory and immune responses by regulating the activities of RTF. RTF
prevents ATP activation of P2Z, thus preventing the cell from undergoing pro-inflammatory activation and apoptosis.
SUMMARY OF THE INVENTION
The present invention is directed to compositions and methods to modulate inflamnzatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). Immune activation can be accomplished by inhibiting the RTF
activity.
In one embodiment, the RTF activity can be inhibited by administering a RTF
antagonist, which can be a small molecule, a peptide, or an antibody or a fragment thereof. Inhibiting the RTF activity may result in cell apotosis, especially cancer cells such as ovarian carcinoma cells.
Inflammatory responses can be inhibited by increasing the level of activity of RTF. In an embodiment, the method of increasing the level of activity of RTF
is by administering an effective amount of RTF or a fragment of RTF. The RTF or its fragment can be isolated or purified from mammalian cells such as the T-lymphocyte, the B-lymphocyte, the macrophage, thyinus, or the fetalplacental tissue.
Alternatively, the RTF can be synthetic or a recombinant RTF.
The present invention is also directed to a method of treating cancer, such as ovarian cancer, by iiihibiting the RTF activity. In one embodiment, the method to inhibit RTF activity is to administer an effective dose of a RTF antagonist.
The present invention is further directed to a method of treating or ameliorating an inflammatory disorder or an autoimmune disorder or one or more symptoms thereof by administering an effective amount of RTF or a fragment of RTF. The RTF or its fragment can be isolated or purified from mammalian cells such as the T-lymphocyte, the B-lymphocyte, the macrophage, thymus, or the fetalplacental tissue.
Altematively, the RTF can be synthetic or a recombinant RTF. The RTF can be formulated with one or more suitable pharmaceutical excipients for administration by parenteral, intramuscular, topical, nasal, puhnonary, or oral route. The formulation can also be in the form of micropariicles or nanoparticles. In an embodiment, the method of treating or ameliorating an inflammatory disorder or an autoimmune disorder or one or more symptoms thereof includes an additional step of administering a TNF-a antagonist, which includes but is not limited to infliximab, etanercept, D2E7, CDP571, CDP870, thalidomide and its analogs, and phosphodiesterase type N inhibitors. .
Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.
BRIEF DESCRIPTION OF THE FIGURES
FIG. I shows the expression of RTF and P2Z on PBMC and macrophages. Flow cytometric analysis of the expression of RTF and P2Z. Dotted line indicates isotype control antibody. Solid line represents either RTF expression (column 1) or expression (column 2). The first row represents unstimulated PBMC. The second, row represents PBMC stimulated for 72 hours with PHA. The third row represents macrophages.
FIG. 2 illustrates that RTF expression is concurrent with P2Z expression on lymphocytes during stimulation. Lymphocytes were stimulated with PHA for 0-72 hours. The expression on RTF and P2Z was measured at time points 0, 24hrs, and 72 hrs as indicated by flow cytometry. The Y axis represent the percent maximal expression of each molecule. The black bars represent RTF expression and the gray bars represent P2Z expression. Error bars represent the standard error of the mean. .
FIG. 3 shows that RTF moves to the surface of the membrane in a 50 kDa form during activation. PBMC were stimulated for 0-72 hours and RTF size was examined by westem blot and RTF location was examined by confocal microscopy. Panel A:
Western Blot: PBMC were stimulated with plate bound CD3 and CD28 and harvested at the time points indicated (in hours), western blotted and probed by 2C1. Row 1 represents proteins of 70 kDa size, and row 2 represents proteins of 50 kDa size. Each lane represents a stimulation time of 0, 18, 48, and 72 hours respectively.
Panel B:
Confocal Microscopy: Confocal microscopy images of PBMC taken before activation (left panel) and at 72 hrs of activation (right panel), permeabilized and stained with anti-RTF-FITC and counterstained with anti-CD8-PE.
FIG. 4 demonstrates that surface ATPase activity is inhibited by anti-RTF.
PBMC and J774A1 macrophages with anti-RTF antibody (black columns) or isotype control antibody (gray columns) were examined for surface ATPase activity, by adding [32]yP-ATP and measuring the release of [32]-Pi. The Y axis represents surface ATPase activity as measured in counts per minute [32]-Pi. Error bars represent the standard error of the mean.
FIG. 5 shows that anti-RTF asid ATP generate more apoptosis together than either alone. Top row represent flow cytometry histograms of J774A1 macrophages incubated with ATP, anti-RTF, or both together. Bottom row represents J774A1 cells incubated with ATP, anti-RTF, and different concentrations of ATPase as indicated. X
axis represents annexin-V staining. Means of four independent experiments with standard error are given for each.
FIG. 6 demonstrates the enhancement of secretion of IL-1(3 in THP-1 Macrophages by anti-RTF antibody.
FIG. 7 illustrates the cytotoxic effect of anti-RTF antibody to ovarian carcinoma cells.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject by regulating the level of activity of regeneration and tolerance factor (RTF). Modulating inflammatory and immune responses includes both immune activation and the inhibition of the inflammatory responses. In a preferred embodiment, the subject is a mammal. In a more preferred einbodiment, the subject is a human.
A principle means by which RTF controls the extent of inflamination is via its interaction with P2Z, a cell surface receptor expressed primarily on cells of hematopoetic origin such as lymphocytes and macrophages. P2Z is one of a family of receptors known as purinoceptors which are activated by nucleotides.
Extracellular ATP binds P2Z, which triggers the opening of specific calcium channels as well as non-specific transmembrane channels (Dubyalc, G.R. and C. el-Moatassim, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.
Am J Physiol, 1993. 265(3 Pt 1): p. C577-606; Gargett, C.E., J.E. Comish, and J.S.
Wiley, ATP, a partial agonist for the P2Z receptor of human lynzphocytes. Br J
Pharmacol, 1997. 122(5): p. 911-7; Zheng, L.M., et al., Extracellular ATP as a trigger for apoptosis or pnogranzmed cell death. J Cell Biol, 1991. 112(2): p. 279-88). These channels then allow for rapid influx of calcium ions into the cytosolic space.
This calcium influx in turn drives forward many specific activation pathways. The activation of P2Z can cause specific activation of NF-xB, and the maturation and secretion of IL-1 R, a potent inflammatory cytokine. This will subsequently increase both cellular activation and drive the inflainmatory response, making P2Z a key mediator in the inflammatory process. It can also cause apoptosis and an inflammatory counterpart to apoptosis, oncosis, inducing the release of further ATP. Recent reports have shown that the absence of the P2Z purinoceptor can attenuate the inflammatory response (Labasi JM, P.N., Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol, 2002. 168(12)(Jun 15): p. 6436-45).
Therefore it follows that extracellular ATP up-regulates the inflammatory response through its instigation of P2Z activation at the site of inflammation and also the stimulated release of pro-inflammatory cytokines. A key regulatory point at which to reduce the inflammatory response, then, is in the concentration of extracellular ATP..
It has been suggested that ecto-ATPases hold important regulatory surface ATPase activity, which attenuates inflainmatory as well as iininune responses (Labasi JM, P.N., Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wiclcs JR, Audoly L, Gabel CA., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflamnzatoi-y response. J Immunol, 2002. 168(12)(Jun 15): p. 6436-45;
Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lym.plzocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem, 1990. 265(1): p. 334-40). The present application discloses that RTF is the primary surface ATPase with this function.
RTF is the a-subunit of a2-isoform of vacuolar ATPase, and that RTF exists as a 70 kDa protein (Toyomura, T., et al., Three subunit a isofornzs of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isofoYm during osteoclast diferentiation. J
Biol Chem, 2000. 275(12): p. 8760-5; Nichols, T.C., et al., Expression of a membYane forrn of the pregnancy-associated protein TJ6 on lynzphocytes. Cell Immunol, 1994.
FIG. 4 demonstrates that surface ATPase activity is inhibited by anti-RTF.
PBMC and J774A1 macrophages with anti-RTF antibody (black columns) or isotype control antibody (gray columns) were examined for surface ATPase activity, by adding [32]yP-ATP and measuring the release of [32]-Pi. The Y axis represents surface ATPase activity as measured in counts per minute [32]-Pi. Error bars represent the standard error of the mean.
FIG. 5 shows that anti-RTF asid ATP generate more apoptosis together than either alone. Top row represent flow cytometry histograms of J774A1 macrophages incubated with ATP, anti-RTF, or both together. Bottom row represents J774A1 cells incubated with ATP, anti-RTF, and different concentrations of ATPase as indicated. X
axis represents annexin-V staining. Means of four independent experiments with standard error are given for each.
FIG. 6 demonstrates the enhancement of secretion of IL-1(3 in THP-1 Macrophages by anti-RTF antibody.
FIG. 7 illustrates the cytotoxic effect of anti-RTF antibody to ovarian carcinoma cells.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject by regulating the level of activity of regeneration and tolerance factor (RTF). Modulating inflammatory and immune responses includes both immune activation and the inhibition of the inflammatory responses. In a preferred embodiment, the subject is a mammal. In a more preferred einbodiment, the subject is a human.
A principle means by which RTF controls the extent of inflamination is via its interaction with P2Z, a cell surface receptor expressed primarily on cells of hematopoetic origin such as lymphocytes and macrophages. P2Z is one of a family of receptors known as purinoceptors which are activated by nucleotides.
Extracellular ATP binds P2Z, which triggers the opening of specific calcium channels as well as non-specific transmembrane channels (Dubyalc, G.R. and C. el-Moatassim, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides.
Am J Physiol, 1993. 265(3 Pt 1): p. C577-606; Gargett, C.E., J.E. Comish, and J.S.
Wiley, ATP, a partial agonist for the P2Z receptor of human lynzphocytes. Br J
Pharmacol, 1997. 122(5): p. 911-7; Zheng, L.M., et al., Extracellular ATP as a trigger for apoptosis or pnogranzmed cell death. J Cell Biol, 1991. 112(2): p. 279-88). These channels then allow for rapid influx of calcium ions into the cytosolic space.
This calcium influx in turn drives forward many specific activation pathways. The activation of P2Z can cause specific activation of NF-xB, and the maturation and secretion of IL-1 R, a potent inflammatory cytokine. This will subsequently increase both cellular activation and drive the inflainmatory response, making P2Z a key mediator in the inflammatory process. It can also cause apoptosis and an inflammatory counterpart to apoptosis, oncosis, inducing the release of further ATP. Recent reports have shown that the absence of the P2Z purinoceptor can attenuate the inflammatory response (Labasi JM, P.N., Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol, 2002. 168(12)(Jun 15): p. 6436-45).
Therefore it follows that extracellular ATP up-regulates the inflammatory response through its instigation of P2Z activation at the site of inflammation and also the stimulated release of pro-inflammatory cytokines. A key regulatory point at which to reduce the inflammatory response, then, is in the concentration of extracellular ATP..
It has been suggested that ecto-ATPases hold important regulatory surface ATPase activity, which attenuates inflainmatory as well as iininune responses (Labasi JM, P.N., Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wiclcs JR, Audoly L, Gabel CA., Absence of the P2X7 receptor alters leukocyte function and attenuates an inflamnzatoi-y response. J Immunol, 2002. 168(12)(Jun 15): p. 6436-45;
Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lym.plzocytes. Protection from the cytolytic effects of extracellular ATP. J Biol Chem, 1990. 265(1): p. 334-40). The present application discloses that RTF is the primary surface ATPase with this function.
RTF is the a-subunit of a2-isoform of vacuolar ATPase, and that RTF exists as a 70 kDa protein (Toyomura, T., et al., Three subunit a isofornzs of mouse vacuolar H(+)-ATPase. Preferential expression of the a3 isofoYm during osteoclast diferentiation. J
Biol Chem, 2000. 275(12): p. 8760-5; Nichols, T.C., et al., Expression of a membYane forrn of the pregnancy-associated protein TJ6 on lynzphocytes. Cell Immunol, 1994.
155(1): p. 219-29; Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell activation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-71). A 20 kDa fragment can be cleaved, leaving the 50 kDa external membrane form (Nichols, T.C., et al., Expression of a meinbrane forin of the pyegnancy-associated protein TJ6 on lymphocytes. Cell Iinmunol, 1994. 155(1): p. 219-29). Current data support that RTF is known to have a role in certain forms of apoptosis (Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell activation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-71; Boomer, J.S., et al., Regeneration and tolerance factor is expressed during T-lymphocyte activation an.d plays a role in apoptosis. Hum Immunol, 2001. 62(6): p. 577-88). It has also been shown equally that anti-RTF antibody can bloclc RTF's ATPase activity, subsequently allowing ATP to bind P2Z and induce apoptosis. It has additionally been shown that RTF works in an antagonistic fashion versus the P2Z surface purinoceptor. United States Patent No. 6,133,434 and International Patent Application (PCT) No. WO 95/33048 disclose that antibodies against P2Z receptors can be useful in treating a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of innnune system, irritable bowel syndrome and premature ejaculation.
One possible mechanism for RTF to modulate inflammatory and immune responses is by RTF acting as an ATPase to reduce the level of extracellular ATP. ATP, released during injury or stress from tissues, infiltrating cells, and dying cells at the site of inflainmation, interacts with the P2Z receptor. This interaction exacerbates the inflammatory response which leads to cell activation and the maturation and secretion of IL-1(3. By controlling the degradation of extracellular ATP, RTF down regulates immune responses, including immune activation and inflamination. Thus, inhibiting the RTF activity leads to irmnune activation, which may lead to cell death, while enhancing the RTF activity leads to inhibition of inflammatory responses.
Any metliod that inhibits RTF activity can be employed in the present invention for immune activation. In a preferred embodiment, the method to inhibit RTF is by administering a RTF antagonist. The RTF antagonist can be a small molecule, a peptide, an antibody or a fragment thereof, and the like. The antibody can be either polyclonal or monoclonal. In one embodiment, the antagonist acts by binding to RTF to inhibit its activity. A preferred RTF antagonist is an anti-RTF antibody or a fragment thereof, and a preferred anti-RTF antibody is a monoclonal RTF antibody or a fragment thereof. A method to produce and purify a monoclonal RTF antibody is disclosed by Boomer et al. (Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell actfvation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-71).
In another embodiment, the antagonist acts by inln'biting cellular expression of RTF. An example of such an antagonist includes, but is not limited to, an antisense nucleic acid which binds to the DNA codi.ng for the RTF molecule. Using antisense nucleic acid to bind to DNA
to inhibit cellular expression of proteins is well known in the art. Another example of antagonizing RTF is by inducing RNA interference (RNAi). The RNAi process induces the degradation of the target gene mRNA so as to silence the target gene expression. A
typical RNAi process includes inttoducing into cells a double-stranded interfering RNA
that comprises a sense RNA having the sequence homologous to the target gene mRNA
and antisense RNA having the sequence complementary to the sense RNA. The double-stranded interfering RNA can be a small interfering double stranded RNA (also known as siRNA). The double-stranded interfering RNA can be introduced to the cells exogenously, or it can be expressed intracellular by incorporating into the cells an expression system to express the double-stranded interfering RNA.
Intracellular expression is preferred for siRNA.
The RTF autagonist can be prepared as a pharmaceutical formulation by including one or more suitable or appropriate excipients. In an embodiment, the pharmaceutical formulation is a nanoparticle or a microparticle. The antagonist can be administered to the subject by any route including but not limited to parenteral, topical, nasal, pulmonary, ophthalmic, bucal, vaginal, transdermal, intrathecal, and oral One of the results of inhibiting RTF activity is induction of cell apotosis, especially cancer cells, such as ovarian carcinoma cells. Thus, inhibiting RTF
can be used as a method to treat cancer. Any of the methods described above which inhibit RTF can then be used as a method to treat cancer. An example of cancer that can be treated in the present invention is ovarian cancer.
Since inflammatory responses are the result of immune activation by the injured tissue, it is anticipated that enhancing RTF activity will result in inhibiting the inflammatory responses. Inflammation is known in many disorders which include, but are not limited to, arthritis (including but not limited to rheumatoid arthritis, 7.
spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis), asthina, bronclzitis, menstrual cramps, tendonitis, bursitis, and skin related conditions (such as psoriasis, eczema, bums and dermatitis), certain gastrointestinal conditions (such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis), vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, certain central nervous system disorders (such as Alzheimer's disease and dementia), allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, central nervous system dainage resulting from stroke, ischemia, trauma, and the like. Many of the above inflammatory disorders are autoimmune disorders in which the body develops iminune responses to its own protein. Thus, enhancing the activity of RTF can be used to treat or prevent inflaminatory disorders, including autoiminune disorders, or their sylnptoms.
Any method that enhances the level of activity of RTF can be used to inhibit inflammatory responses and to treat or prevent inflammation in the present invention.
In a preferred embodiment, the method is to administer to the subject an effective amount of RTF or a fragment thereof. In an embodiment, the RTF is an intracellular form which has a molecular weight of about 70 kDa. In another embodiment, the RTF
is extemal meinbrane form having a molecule weight of about 50 kDa.
In one embodiment, the RTF can be isolated or purified from a mammalian source, such as murine or human, which includes but is not limited to, lymphocyte, macrophage, thymus, fetalplacental tissue, and the lilce. The lymphocyte can be a T-lymphocyte or a B-lymphocyte. The T- or B-lymphocyte preferably is activated.
In another embodiment, the RTF or a fragment thereof can be synthetic or a recombinant RTF, which can be derived, for example, from a nucleic acid sequence (e.g. cDNA) encoding the amino acid sequence of the RTF or the fragment. The nucleic acid sequence can be incorporated by recombinant techniques into an appropriate host organism for the expression of the RTF or the fragment. Examples of host organisms include, but are not limited to, bacteria, fitngi, yeasts, protozoa, transgenic animals, transgenic plants, and the like. Recombinant techniques are well known to those skilled in the art and many biopharmaceuticals have been successfully produced by such techniques. A method for producing a recombinant RTF in E. coli is disclosed by Lee et al. (Lee, G. W., Bommer, J,S., Gilman Sachs, A., Chedid A., Gudelj, L., Rukavina, D.
and Beaman, K. D. Regeneration and tolerance factor of the human placenta induces IL-10 itzduction. Eur J Immunol, 2001. 31: p. 687-691) , In a preferred embodiment of the present invention, the RTF or the fragment is formulated with one or more acceptable pharmaceutical excipients for administration to the subject. The RTF or the fragment can also be formulated as microparticles or nanoparticles. The microparticles or nanoparticles can further include ligands to deliver the microparticles or the nanoparticles to a target tissue such as the T- or B-lymphocyte or the macrophage. The RTF or the fragment can be administered to the subject by any acceptable route including, but not limited to, parenteral, topical, nasal, pulmonary, ophthalmic, bucal, vaginal, transderm.al, intrathecal, oral and the like.
In another embodiment, the method to enhance RTF activity can be a method which enhances the expression of cellular RTF.
In yet another embodiment of the present invention, the method of treating inflam.mation by enhancing the RTF activity may include an additional step of administering to the subject a TNF-a antagonist. Since both IUl P and TNF-a are known to cause inflammation, inhibiting the secretion of IL-1 P by RTF and bloclQng, the TNF-a activity by a TNF-a antagonist should have synergistic effects in treating inflammation. There are many known TNF-a antagonists. Examples include, but are not limited to, infliximab, etanercept, D2E7, CDP571, CDP870, thalidomide and its analogs, and phosphodiesterase type IV inhibitors.
EXAMPLES
Example 1: Cell Culture J774A1 cells were maintained by allowing them to adhere to the bottom of a T75 flask with 25 mis of RPMI 1640 complete media at 37 C in a 5% COZ atmosphere.
Cells were split into a new flask every 4 days using trypsin and a gentle wash with RPMI.
One possible mechanism for RTF to modulate inflammatory and immune responses is by RTF acting as an ATPase to reduce the level of extracellular ATP. ATP, released during injury or stress from tissues, infiltrating cells, and dying cells at the site of inflainmation, interacts with the P2Z receptor. This interaction exacerbates the inflammatory response which leads to cell activation and the maturation and secretion of IL-1(3. By controlling the degradation of extracellular ATP, RTF down regulates immune responses, including immune activation and inflamination. Thus, inhibiting the RTF activity leads to irmnune activation, which may lead to cell death, while enhancing the RTF activity leads to inhibition of inflammatory responses.
Any metliod that inhibits RTF activity can be employed in the present invention for immune activation. In a preferred embodiment, the method to inhibit RTF is by administering a RTF antagonist. The RTF antagonist can be a small molecule, a peptide, an antibody or a fragment thereof, and the like. The antibody can be either polyclonal or monoclonal. In one embodiment, the antagonist acts by binding to RTF to inhibit its activity. A preferred RTF antagonist is an anti-RTF antibody or a fragment thereof, and a preferred anti-RTF antibody is a monoclonal RTF antibody or a fragment thereof. A method to produce and purify a monoclonal RTF antibody is disclosed by Boomer et al. (Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell actfvation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-71).
In another embodiment, the antagonist acts by inln'biting cellular expression of RTF. An example of such an antagonist includes, but is not limited to, an antisense nucleic acid which binds to the DNA codi.ng for the RTF molecule. Using antisense nucleic acid to bind to DNA
to inhibit cellular expression of proteins is well known in the art. Another example of antagonizing RTF is by inducing RNA interference (RNAi). The RNAi process induces the degradation of the target gene mRNA so as to silence the target gene expression. A
typical RNAi process includes inttoducing into cells a double-stranded interfering RNA
that comprises a sense RNA having the sequence homologous to the target gene mRNA
and antisense RNA having the sequence complementary to the sense RNA. The double-stranded interfering RNA can be a small interfering double stranded RNA (also known as siRNA). The double-stranded interfering RNA can be introduced to the cells exogenously, or it can be expressed intracellular by incorporating into the cells an expression system to express the double-stranded interfering RNA.
Intracellular expression is preferred for siRNA.
The RTF autagonist can be prepared as a pharmaceutical formulation by including one or more suitable or appropriate excipients. In an embodiment, the pharmaceutical formulation is a nanoparticle or a microparticle. The antagonist can be administered to the subject by any route including but not limited to parenteral, topical, nasal, pulmonary, ophthalmic, bucal, vaginal, transdermal, intrathecal, and oral One of the results of inhibiting RTF activity is induction of cell apotosis, especially cancer cells, such as ovarian carcinoma cells. Thus, inhibiting RTF
can be used as a method to treat cancer. Any of the methods described above which inhibit RTF can then be used as a method to treat cancer. An example of cancer that can be treated in the present invention is ovarian cancer.
Since inflammatory responses are the result of immune activation by the injured tissue, it is anticipated that enhancing RTF activity will result in inhibiting the inflammatory responses. Inflammation is known in many disorders which include, but are not limited to, arthritis (including but not limited to rheumatoid arthritis, 7.
spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis), asthina, bronclzitis, menstrual cramps, tendonitis, bursitis, and skin related conditions (such as psoriasis, eczema, bums and dermatitis), certain gastrointestinal conditions (such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis), vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, certain central nervous system disorders (such as Alzheimer's disease and dementia), allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, central nervous system dainage resulting from stroke, ischemia, trauma, and the like. Many of the above inflammatory disorders are autoimmune disorders in which the body develops iminune responses to its own protein. Thus, enhancing the activity of RTF can be used to treat or prevent inflaminatory disorders, including autoiminune disorders, or their sylnptoms.
Any method that enhances the level of activity of RTF can be used to inhibit inflammatory responses and to treat or prevent inflammation in the present invention.
In a preferred embodiment, the method is to administer to the subject an effective amount of RTF or a fragment thereof. In an embodiment, the RTF is an intracellular form which has a molecular weight of about 70 kDa. In another embodiment, the RTF
is extemal meinbrane form having a molecule weight of about 50 kDa.
In one embodiment, the RTF can be isolated or purified from a mammalian source, such as murine or human, which includes but is not limited to, lymphocyte, macrophage, thymus, fetalplacental tissue, and the lilce. The lymphocyte can be a T-lymphocyte or a B-lymphocyte. The T- or B-lymphocyte preferably is activated.
In another embodiment, the RTF or a fragment thereof can be synthetic or a recombinant RTF, which can be derived, for example, from a nucleic acid sequence (e.g. cDNA) encoding the amino acid sequence of the RTF or the fragment. The nucleic acid sequence can be incorporated by recombinant techniques into an appropriate host organism for the expression of the RTF or the fragment. Examples of host organisms include, but are not limited to, bacteria, fitngi, yeasts, protozoa, transgenic animals, transgenic plants, and the like. Recombinant techniques are well known to those skilled in the art and many biopharmaceuticals have been successfully produced by such techniques. A method for producing a recombinant RTF in E. coli is disclosed by Lee et al. (Lee, G. W., Bommer, J,S., Gilman Sachs, A., Chedid A., Gudelj, L., Rukavina, D.
and Beaman, K. D. Regeneration and tolerance factor of the human placenta induces IL-10 itzduction. Eur J Immunol, 2001. 31: p. 687-691) , In a preferred embodiment of the present invention, the RTF or the fragment is formulated with one or more acceptable pharmaceutical excipients for administration to the subject. The RTF or the fragment can also be formulated as microparticles or nanoparticles. The microparticles or nanoparticles can further include ligands to deliver the microparticles or the nanoparticles to a target tissue such as the T- or B-lymphocyte or the macrophage. The RTF or the fragment can be administered to the subject by any acceptable route including, but not limited to, parenteral, topical, nasal, pulmonary, ophthalmic, bucal, vaginal, transderm.al, intrathecal, oral and the like.
In another embodiment, the method to enhance RTF activity can be a method which enhances the expression of cellular RTF.
In yet another embodiment of the present invention, the method of treating inflam.mation by enhancing the RTF activity may include an additional step of administering to the subject a TNF-a antagonist. Since both IUl P and TNF-a are known to cause inflammation, inhibiting the secretion of IL-1 P by RTF and bloclQng, the TNF-a activity by a TNF-a antagonist should have synergistic effects in treating inflammation. There are many known TNF-a antagonists. Examples include, but are not limited to, infliximab, etanercept, D2E7, CDP571, CDP870, thalidomide and its analogs, and phosphodiesterase type IV inhibitors.
EXAMPLES
Example 1: Cell Culture J774A1 cells were maintained by allowing them to adhere to the bottom of a T75 flask with 25 mis of RPMI 1640 complete media at 37 C in a 5% COZ atmosphere.
Cells were split into a new flask every 4 days using trypsin and a gentle wash with RPMI.
Example 2: ATPase Assay PBMC or J774A1 macrophages were suspended in 50 1 of RPMI at a density of 2.5x105 in a 96 well flat bottom plate and incubated with 10 g of either 2C1 (anti-RTF) or an isotype matched control antibody for 45 mins at 37 C in a 5% CO2 atmosphere.
Cells were washed with PBS and re-suspended in 100 1 of assay buffer (5mM KC1, 2mM CaC12, 2mM MgC12, and 1.5 C of [y-32P]ATP) in 1.5m1 eppendorf tubes. The ATPase reaction was allowed to continue for 10 mins at room teinperature. 500 1 of 20% w/v activated charcoal (in distilled water) was added to scavenge any unused [7-32P]ATP and allowed to sit for 10 mins on ice. The cells were centrifuged at 3200 x g for 5 mins, pelleting the charcoal. 500 1 of supernatant containing released y-32P was removed and added to scintillation vials wit113mis of scintillation fluid and read in the scintillation counter for 1 min/tube (Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lymphocytes. Protection ftom the cytolytic effects of extracellular ATP. J
Biol Chem, 1990. 265(1): p. 334-40; Doinbrowski, K.E., et al., Identification and partial characterization of an ectoATPase expressed by human natural killer cells.
Biochemistry, 1993. 32(26): p. 6515-22; Dombrowski, K.E., et al., Antigen f ecognition by CTL is dependent upon ectoATPase activity. J Imtnunol, 1995. 154(12):
p..6227-37).
Example 3: Apoptosis Induction Approximately 2.5x105 PBMC were suspended in 100 1 of RPMI in a 96 well round bottom plate and a final concentration of either 3mM ATP, 0.75mM ATP, 10 g anti-RTF, or 0.751nM ATP + 10 g anti-RTF together was added. Cells were incubated in these conditions at 37 C in 5% CO2 for 6 hours. Cells were washed twice in 0.01%
BSA/PBS, and re-suspended in 100 1 binding buffer (10mM HEPES pH 7.4, 140mM
NaCI, 2.5mM CaC12) with 5 l of annexin-V/FITC (BD/Pharmingen) for 15 mins.
Cells were washed in binding buffer and re-suspended in 300 1 of binding buffer with 3 l of lmg/ml propidium iodide. Apoptosis was measured by quantifying annexin-V
binding by flow cytometry by gating on PI-/annexin-V+ cells (Vermes, L, et al., A
novel assay for apoptosis. Flow cytonaetr-ic detection of phosphatidylserine expression on eaf-ly apoptotic cells using fluorescein labeled Annexin V. J Im.munol Methods, 1995.
184(1):
p. 39-51).
Example 4: P2Z and RTF Staining A total of 2.5x105 cells were washed twice with 0.01 %BSA/PBS for 5 mins and re-suspended in 100nl of staining buffer. 5 1 of rabbit anti-P2X7 (P2Z) (Chemicon) antibody, 5 1 anti-RTF-FITC, or 51il of isotype matched control antibody was added to the appropriate tubes and allowed in react in the dark for 15 mins. Cell were washed again and re-suspended in 100 1 of staining buffer (1X PBS, 5% FBS) with 5 I
of anti-Rabbit biotinylated antibody (Pharmingen) and allowed to react for 15 mins. A
third wash was performed and 20 of Streptavidin-PE (Pharmingen) was added for 15 mins.
After a final wash, the cells were re-suspended in 300 1 of staining buffer and run on a BD Facscalibur flow cytometer.
Example 5: Propidium Iodide and Lucifer Yellow Incflraoration J774 cells were suspended in 100 .1 of RPMI in a 96 well round bottom plate at a density of 2.5x105 in on of the following conditions: 3mM ATP, 0.75mM ATP, 50 g anti-RTF, or 0.75mM ATP + 10 g anti-RTF. Cells were incubated at 37 C in 5%
for 30 mins in the presence of l g PI or LY, washed in PBS, re-suspended in PBS and analyzed in the BD FACSCALIBURTM flow cytometer.
For slides, J774 cells were grown in 4 well chamber slides for 2 days. The supematant was removed and each chamber was incubated in one of the conditions described above for 15 mins in the presence of 1 g PI or LY. The slides were washed in PBS, and incubated with l0 Trypan blue for 5 mins, washed again and examined under a fluorescent microscope.
Example 6: Confocal Microscopy PBMC were obtained by FICOLLTM separation and 2.5x105 cells per well were incubated in a 96 we11 plate in RPMI 1640 medium in the presence of 2 g/ml PHA, or RPMI alone. After 72 hours both unstimulated, and stimulated cells were washed twice in PBS, permeabilized with ice cold 70% ethanol for 15 mins, and reacted with 7 l anti-RTF-FITC, anti-CD8-PE (Pharmingen), or isotype control antibody for 15 mins.
Cells were washed again, fixed with Coulter fixative solution, and a CYTOSPINTM was used to transfer them to a positively charged slide which was mounted with Dapco medium.
Slides were then exanmined by confocal microscopy.
Exainple 7: RTF Expression Follows P2Z Expression on Lymphocytes It has been previously shown that RTF expression in lymphocytes is dependent on activation (Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell activation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-7). To characterize RTF expression in relation to P2Z expression during the immune response, the surface expression of RTF and P2Z on lymphocytes was measured following stimulation with PHA for 24-72 hours. In resting lymphocytes, RTF expression was 14.42 0.06% that of maximal expression while P2Z expression was 35.23 8.5%.
RTF and P2Z expression increased togetller on the surface of the cells as stimulation time increased, with RTF and P2Z expression at 88.64 8.8% and 81.34 13.2%
respectively at 72 hours (Figure 1). Both molecules matched the others percent maximal expression at 0 and 24 hours, reaching maximal expression at 72 hours (Figure 2)..
The expression of RTF and P2Z on the J774A1 macrophage cell line has also been examined. Figure 1 shows that each molecule to be expressed in a constitutive manner.
Example 8: RTF Exists as a 50 kDa Protein on the Surface of Activated Cells, and as a 70 kDa Protein Inside of Resting Cells When lymphocytes examined by western blot at the time points stimulated above (Figure 3a), unstimulated lymphocytes expressed a 70 kDa protein of RTF as their major form of RTF. Upon stimulation, expression of RTF fell below detectable levels at a time period of 16-24 hours. At a time period of 24-72 hours after stimulation RTF
expression returned to detectable levels, however predominantly in a 50 kDa sized form (Figure 3a).
It is hypothesized that the 70 kDa form represents the intracellular form of RTF, while the 50 kDa form represents the external membrane fonn. To test this, the activated lymphocytes from Figure 3a were further examined by confocal microscopy at 0 and 72 hours of stimulation (Figure 3b). In this figure RTF (green) is present in the cytoplasm of un-stimulated cells. In cells stimulated with PHA for 72 hrs, RTF
has re-localized to the surface of the membrane. Consistent with the western blot shown in Figure 3a, these findings suggest to us that the 70 kDa protein is intracellular in resting lymphocytes, whereas the 50 lcDa protein is found on the surface of activated lymphocytes.
Example 9: RTF Regulates Surface ATPase Activity in Lymphocytes and Macrophages It is hypothesized that RTF regulates surface ATPase activity and anti-RTF
blocks it. To demonstrate that RTF has surface ATPase activity, PBMC and macrophages were incubated with either anti-RTF or isotype control antibody for 45 mins, and their surface ATPase activity was measured by [y32-P]ATP degradation (Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lynaphocytes.
Protection fy-onz the cytolytic effects of extracellular ATP. J Biol Chem, 1990. 265(1): p. 334-40;
Dombrowski, K.E., et al., Identification and partial characterization of an ectoATPase expressed by hufnan natural killer cells. Biochemistry, 1993. 32(26): p. 6515-22;
Dombrowski, K.E., et al., Antigen recognition by CTL is dependent upon ectoATPase activity. J Iinmunol, 1995. 154(12): p. 6227-37). The PBMC incubated with anti-RTF
had a 10 fold decrease in surface ATPase activity with 11,758 3,394 cpm compared to PBMC incubated witli isotype antibody with a cpm of 115,592 23,891.
(P<0.001;
Figure 4). The J774A1 cells incubated with anti-RTF had a complete iiiliibition of surface ATPase activity compared with the isotype control (45,752 16,175 cpm;
P<0.001; fig 4). Thin layer chromatography confinned that anti-RTF completely iiiliibited the surface ATPase activity (data not shown).
Example 10: RTF Prevents ATP from Inducing Apoptosis Since RTF moves to the surface of the membrane as a 50 kDa size protein after stimulation in PBMC, and RTF regulates ATPase activity, it is desirable to demonstrate that RTF can prevent ATP induced apoptosis. For this purpose the macrophage cell line J774A1 is chosen. J774A1 cells were to be used as a model to demonstrate the interaction of RTF with P2Z because this cell line expresses both molecules constitutively and is known to undergo P2Z mediated, ATP induced apoptosis (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in ifnnaunity, inf anaination and cell death. Immunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M.
Persechini, P2Z purinoceptor-associated pores induced by extracellular ATP in niacrophages and J774 cells. Ain J Physiol, 1997. 273(6 Pt 1): p. C1793-800).
If the theory that RTF regulates surface ATPase activity and therefore regulates ATP
binding to P2Z is correct, then it follows that anti-RTF and ATP would work together to generate more apoptosis than either alone by blocking the ATPase activity of RTF.
When added together, at the same concentration as both alone, a near maximal amount of apoptosis occurred as measured by annexin-V (Figure 5). When 3mM ATP was added, 84.14 1.63 % of the cells underwent apoptosis, but when the amount of ATP
was decreased to 0.75mM, only 13.26 3.6% apoptosis was seen. When 10 g of anti-RTF was added alone, 15.49. 4.05% of the cells were apoptotic. However, anti-RTF
and 0.75mM ATP were added together, apoptosis was 83.05 5.09%. When ATPase was added back, no apoptosis occurred showing that RTF's apoptosis inducing ability is dependent on the presence of ATP (Figure 5). Previously, in initial experiments we demonstrated that anti-RTF had no effect on the ATPase used, negating the possibility of their interaction (data not shown).
Example 11: RTF Prevents P2Z Activation A standard teclmique for detecting P2Z activity is used to demonstrate that the ultimate cause of the apoptosis inducing effect of RTF and ATP was due to P2Z
activation (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in imnzunity, inflammation and cell death. Immunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M. Persechini, P2Z pur-inoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells. Am J Physiol, 1997. 273(6 Pt 1): p. C1793-800;
Steinberg, T.H., et al., ATP4- permeabilizes the plasma menzbrane of mouse macrophages to fluorescen.t dyes. J Biol Chem, 1987. 262(18): p. 8884-8). When ATP
interacts with P2Z, non-specific channels of about 0.9 kDa in size will open in the membrane (Dubyak, G.R. and C. el-Moatassim, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Atn J Physiol, 1993.
265(3 Pt 1):
p. C577-606; Di Virgilio, F., The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today, 1995. 16(11): p. 524-8; Hickman, S.E., et al., P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood, 1994. 84(8): p. 2452-6; Greenberg, S., et al., Extracellular nucleotides nzediate Ca2+ fluxes in. J774 macrophages by two distinct n2echanisnzs. J
Biol Chem, 1988. 263(21): p. 10337-43). This allows the testing for P2Z's influence by measuring the influx of molecules smaller than 0.9 kDa, to which the cell is normally not permeable. Propidium iodide (PI) (0.414 kDa) and lucifer yellow (LY) (0.46 kDa) should be allowed through if P2Z is activated, and trypan blue (TB) (0.96 kDa) should be excluded under all circumstances unless necrosis has occurred (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death.
Imn.iunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M.
Persechini, P2Z
purinoceptor-associated pores induced by extracellular ATP in inacrophages and cells. Am J Physiol, 1997. 273(6 Pt 1): p. C1793-800; Steinberg, T.H., et al., pe>^meabilizes the plasma zzzeznbrane of mouse macrophages to fluorescent dyes. J Biol Chem, 1987. 262(18): p. 8884-8). The same conditions used in the previous experiment were repeated to observe and measure the entry of propidium iodide or trypan blue in J774A1 cells. Thus P2Z influence would be characterized by cells that were PI
and LY
positive but TB negative.
Using flow cytometry, cells incubated with anti-RTF + 0.75mM ATP had pronounced channel formation judging from their incorporation of PI (Figure 6). This was confirmed by immunofluorescence microscopy (Figure 6). Cells reacted with anti-RTF and 0.75mM ATP together were found to be permeable to PI, but not to trypan blue (Figure 6). In contrast, control cells permeabilized with 70% ETOH were positive for both dyes (data not shown). Cells that were incubated with anti-RTF alone or 0.75mM ATP alone (Figure 6) showed no PI incorporation, while those incubated with both did incorporate PI. These results were confirmed using lucifer yellow (not shown).
This demonstrates that anti-RTF and ATP togetlier can induce the opening of channels >0.9 kDa, and yet shows membrane integrity is still intact.
Example 12: RTF regulates IL-1(3 secretion To show that RTF regulates IL-1p secretion, THP-1 macrophages were incubated with both 1mM and 3mM ATP, or anti-RTF and assayed for IL-1(3 secretion by ELISA. Since anti-RTF abrogates RTF function, our hypothesis was that anti-RTF
would induce IL-(3 secretion, showing that RTF is a regulator for this molecule.
5x105 THP macrophage cells were stimulated with 5nghnl of LPS and 1x105 PBMC for 2.5 hours. These cells were then washed and iiicubated in a final concentration of either 0 ATP, 3mM ATP, 1mM ATP, or anti-RTF for a period of 3 hours. The supernatants were assayed for IL-1(3 by ELISA (R&D systems). pg IL-1(3 per well was calculated from the optical densities. Results are expressed as the mean of 3 independent experiments.
As shown in Figure 7, cells incubated with media alone, secreted 61+1-14 pg IL-1 j3, forming the baseli.ne. Cells incubated with 3mM ATP secreted 285+/-25 pg (78+/-5.1% above baseline). Cells incubated with 1.mM ATP secreted 130+/-44 pg IL-1(3 (49+/-5.6 above baseline). Ce1Ls incubated with anti-RTF alone secreted 114 +/-22 pg IIrl (3 (an increase 47+1-3.5%), about the equivalent of cells incubated with 1mM ATP.
This shows that anti-RTF alone can induce secretion, suggesting that RTF is a regulator oflL-1(i.
Example 13: Anti-RTF is-cytotoxic to ovarian carcinoma cell A2780 ovarian carcinoma cells were grown in 96 well plates until 100%
confluent. Wells were identified, and cells were then incubated with 3mM ATP, 6mM
ATP, 20 g of anti-RTF and 20 ug of anti-RTF combined with 3mM ATP and 6mM
ATP. Cells were incubated for 18 hours at 37 C in a 5% CO 2 environment. Cells were then harvested and assayed using flow cytometry for Caspase 3 activation as an indicator for cell death. As shown in Figure 8, anti-RTF is significantly more cytotoxic then extracellular ATP at the indicated concentrations. Addition of extracellular ATP
did not significantly enhance cytotoxicity.
Example 14. In vivo effect of anti-RTF
Female athymic nude mice purchased from Harlan Sprague Dawley approximately 11 weeks old. All mice were injected with 200 1 of a 1:1 slurry of a MATRIGELTM mix containing 5x 106 A2780 ovarian carcinoma cells. Tumor cells were transplanted subcutaneously in the upper flank of the right leg. Two mice were untreated and kept as a control to measure tumor growth. The remaining six mice were injected with anti RTF antibody. All mice were left untreated for I week in order for a tumor and its vascular bed to become established. On the eighth day all mice that were treated were injected with 100ug of anti RTF antibody in a volume of 100 1 of PBS.
Injections were given in the tumor bearing flank of the animal. Antibody was not injected directly into the tumor, but was injected into the area of the tumor bed. Mice received 300 g of antibody per week using a 28 gage needle. Mice were injected every Sunday, Tuesday and Friday. Injections took place over 5 weeks. The experiment was terminated when the control mice tumor burden became too obstructive for mice to ambulate.
The median tumor volume of the control animals after 5 weeks without anti-RTF
treatment was 8448 mm3 . The median tumor volume for the anti-RTF treated animals(n=6) was 364 mm3. In two of the treated animals no measurable tuinor was observed (tumor volume range 0-1670). These results clearly indicate the possible usefiilness of the antibody and or the inhibition of the RTF associated ATPase complex in tumor therapy It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art.
Such changes and modifications can be made witliout departing fiom the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Cells were washed with PBS and re-suspended in 100 1 of assay buffer (5mM KC1, 2mM CaC12, 2mM MgC12, and 1.5 C of [y-32P]ATP) in 1.5m1 eppendorf tubes. The ATPase reaction was allowed to continue for 10 mins at room teinperature. 500 1 of 20% w/v activated charcoal (in distilled water) was added to scavenge any unused [7-32P]ATP and allowed to sit for 10 mins on ice. The cells were centrifuged at 3200 x g for 5 mins, pelleting the charcoal. 500 1 of supernatant containing released y-32P was removed and added to scintillation vials wit113mis of scintillation fluid and read in the scintillation counter for 1 min/tube (Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lymphocytes. Protection ftom the cytolytic effects of extracellular ATP. J
Biol Chem, 1990. 265(1): p. 334-40; Doinbrowski, K.E., et al., Identification and partial characterization of an ectoATPase expressed by human natural killer cells.
Biochemistry, 1993. 32(26): p. 6515-22; Dombrowski, K.E., et al., Antigen f ecognition by CTL is dependent upon ectoATPase activity. J Imtnunol, 1995. 154(12):
p..6227-37).
Example 3: Apoptosis Induction Approximately 2.5x105 PBMC were suspended in 100 1 of RPMI in a 96 well round bottom plate and a final concentration of either 3mM ATP, 0.75mM ATP, 10 g anti-RTF, or 0.751nM ATP + 10 g anti-RTF together was added. Cells were incubated in these conditions at 37 C in 5% CO2 for 6 hours. Cells were washed twice in 0.01%
BSA/PBS, and re-suspended in 100 1 binding buffer (10mM HEPES pH 7.4, 140mM
NaCI, 2.5mM CaC12) with 5 l of annexin-V/FITC (BD/Pharmingen) for 15 mins.
Cells were washed in binding buffer and re-suspended in 300 1 of binding buffer with 3 l of lmg/ml propidium iodide. Apoptosis was measured by quantifying annexin-V
binding by flow cytometry by gating on PI-/annexin-V+ cells (Vermes, L, et al., A
novel assay for apoptosis. Flow cytonaetr-ic detection of phosphatidylserine expression on eaf-ly apoptotic cells using fluorescein labeled Annexin V. J Im.munol Methods, 1995.
184(1):
p. 39-51).
Example 4: P2Z and RTF Staining A total of 2.5x105 cells were washed twice with 0.01 %BSA/PBS for 5 mins and re-suspended in 100nl of staining buffer. 5 1 of rabbit anti-P2X7 (P2Z) (Chemicon) antibody, 5 1 anti-RTF-FITC, or 51il of isotype matched control antibody was added to the appropriate tubes and allowed in react in the dark for 15 mins. Cell were washed again and re-suspended in 100 1 of staining buffer (1X PBS, 5% FBS) with 5 I
of anti-Rabbit biotinylated antibody (Pharmingen) and allowed to react for 15 mins. A
third wash was performed and 20 of Streptavidin-PE (Pharmingen) was added for 15 mins.
After a final wash, the cells were re-suspended in 300 1 of staining buffer and run on a BD Facscalibur flow cytometer.
Example 5: Propidium Iodide and Lucifer Yellow Incflraoration J774 cells were suspended in 100 .1 of RPMI in a 96 well round bottom plate at a density of 2.5x105 in on of the following conditions: 3mM ATP, 0.75mM ATP, 50 g anti-RTF, or 0.75mM ATP + 10 g anti-RTF. Cells were incubated at 37 C in 5%
for 30 mins in the presence of l g PI or LY, washed in PBS, re-suspended in PBS and analyzed in the BD FACSCALIBURTM flow cytometer.
For slides, J774 cells were grown in 4 well chamber slides for 2 days. The supematant was removed and each chamber was incubated in one of the conditions described above for 15 mins in the presence of 1 g PI or LY. The slides were washed in PBS, and incubated with l0 Trypan blue for 5 mins, washed again and examined under a fluorescent microscope.
Example 6: Confocal Microscopy PBMC were obtained by FICOLLTM separation and 2.5x105 cells per well were incubated in a 96 we11 plate in RPMI 1640 medium in the presence of 2 g/ml PHA, or RPMI alone. After 72 hours both unstimulated, and stimulated cells were washed twice in PBS, permeabilized with ice cold 70% ethanol for 15 mins, and reacted with 7 l anti-RTF-FITC, anti-CD8-PE (Pharmingen), or isotype control antibody for 15 mins.
Cells were washed again, fixed with Coulter fixative solution, and a CYTOSPINTM was used to transfer them to a positively charged slide which was mounted with Dapco medium.
Slides were then exanmined by confocal microscopy.
Exainple 7: RTF Expression Follows P2Z Expression on Lymphocytes It has been previously shown that RTF expression in lymphocytes is dependent on activation (Boomer, J.S., et al., Regeneration and tolerance factor's potential role in T-cell activation and apoptosis. Hum Immunol, 2000. 61(10): p. 959-7). To characterize RTF expression in relation to P2Z expression during the immune response, the surface expression of RTF and P2Z on lymphocytes was measured following stimulation with PHA for 24-72 hours. In resting lymphocytes, RTF expression was 14.42 0.06% that of maximal expression while P2Z expression was 35.23 8.5%.
RTF and P2Z expression increased togetller on the surface of the cells as stimulation time increased, with RTF and P2Z expression at 88.64 8.8% and 81.34 13.2%
respectively at 72 hours (Figure 1). Both molecules matched the others percent maximal expression at 0 and 24 hours, reaching maximal expression at 72 hours (Figure 2)..
The expression of RTF and P2Z on the J774A1 macrophage cell line has also been examined. Figure 1 shows that each molecule to be expressed in a constitutive manner.
Example 8: RTF Exists as a 50 kDa Protein on the Surface of Activated Cells, and as a 70 kDa Protein Inside of Resting Cells When lymphocytes examined by western blot at the time points stimulated above (Figure 3a), unstimulated lymphocytes expressed a 70 kDa protein of RTF as their major form of RTF. Upon stimulation, expression of RTF fell below detectable levels at a time period of 16-24 hours. At a time period of 24-72 hours after stimulation RTF
expression returned to detectable levels, however predominantly in a 50 kDa sized form (Figure 3a).
It is hypothesized that the 70 kDa form represents the intracellular form of RTF, while the 50 kDa form represents the external membrane fonn. To test this, the activated lymphocytes from Figure 3a were further examined by confocal microscopy at 0 and 72 hours of stimulation (Figure 3b). In this figure RTF (green) is present in the cytoplasm of un-stimulated cells. In cells stimulated with PHA for 72 hrs, RTF
has re-localized to the surface of the membrane. Consistent with the western blot shown in Figure 3a, these findings suggest to us that the 70 kDa protein is intracellular in resting lymphocytes, whereas the 50 lcDa protein is found on the surface of activated lymphocytes.
Example 9: RTF Regulates Surface ATPase Activity in Lymphocytes and Macrophages It is hypothesized that RTF regulates surface ATPase activity and anti-RTF
blocks it. To demonstrate that RTF has surface ATPase activity, PBMC and macrophages were incubated with either anti-RTF or isotype control antibody for 45 mins, and their surface ATPase activity was measured by [y32-P]ATP degradation (Filippini, A., et al., Ecto-ATPase activity in cytolytic T-lynaphocytes.
Protection fy-onz the cytolytic effects of extracellular ATP. J Biol Chem, 1990. 265(1): p. 334-40;
Dombrowski, K.E., et al., Identification and partial characterization of an ectoATPase expressed by hufnan natural killer cells. Biochemistry, 1993. 32(26): p. 6515-22;
Dombrowski, K.E., et al., Antigen recognition by CTL is dependent upon ectoATPase activity. J Iinmunol, 1995. 154(12): p. 6227-37). The PBMC incubated with anti-RTF
had a 10 fold decrease in surface ATPase activity with 11,758 3,394 cpm compared to PBMC incubated witli isotype antibody with a cpm of 115,592 23,891.
(P<0.001;
Figure 4). The J774A1 cells incubated with anti-RTF had a complete iiiliibition of surface ATPase activity compared with the isotype control (45,752 16,175 cpm;
P<0.001; fig 4). Thin layer chromatography confinned that anti-RTF completely iiiliibited the surface ATPase activity (data not shown).
Example 10: RTF Prevents ATP from Inducing Apoptosis Since RTF moves to the surface of the membrane as a 50 kDa size protein after stimulation in PBMC, and RTF regulates ATPase activity, it is desirable to demonstrate that RTF can prevent ATP induced apoptosis. For this purpose the macrophage cell line J774A1 is chosen. J774A1 cells were to be used as a model to demonstrate the interaction of RTF with P2Z because this cell line expresses both molecules constitutively and is known to undergo P2Z mediated, ATP induced apoptosis (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in ifnnaunity, inf anaination and cell death. Immunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M.
Persechini, P2Z purinoceptor-associated pores induced by extracellular ATP in niacrophages and J774 cells. Ain J Physiol, 1997. 273(6 Pt 1): p. C1793-800).
If the theory that RTF regulates surface ATPase activity and therefore regulates ATP
binding to P2Z is correct, then it follows that anti-RTF and ATP would work together to generate more apoptosis than either alone by blocking the ATPase activity of RTF.
When added together, at the same concentration as both alone, a near maximal amount of apoptosis occurred as measured by annexin-V (Figure 5). When 3mM ATP was added, 84.14 1.63 % of the cells underwent apoptosis, but when the amount of ATP
was decreased to 0.75mM, only 13.26 3.6% apoptosis was seen. When 10 g of anti-RTF was added alone, 15.49. 4.05% of the cells were apoptotic. However, anti-RTF
and 0.75mM ATP were added together, apoptosis was 83.05 5.09%. When ATPase was added back, no apoptosis occurred showing that RTF's apoptosis inducing ability is dependent on the presence of ATP (Figure 5). Previously, in initial experiments we demonstrated that anti-RTF had no effect on the ATPase used, negating the possibility of their interaction (data not shown).
Example 11: RTF Prevents P2Z Activation A standard teclmique for detecting P2Z activity is used to demonstrate that the ultimate cause of the apoptosis inducing effect of RTF and ATP was due to P2Z
activation (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in imnzunity, inflammation and cell death. Immunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M. Persechini, P2Z pur-inoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells. Am J Physiol, 1997. 273(6 Pt 1): p. C1793-800;
Steinberg, T.H., et al., ATP4- permeabilizes the plasma menzbrane of mouse macrophages to fluorescen.t dyes. J Biol Chem, 1987. 262(18): p. 8884-8). When ATP
interacts with P2Z, non-specific channels of about 0.9 kDa in size will open in the membrane (Dubyak, G.R. and C. el-Moatassim, Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Atn J Physiol, 1993.
265(3 Pt 1):
p. C577-606; Di Virgilio, F., The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol Today, 1995. 16(11): p. 524-8; Hickman, S.E., et al., P2Z adenosine triphosphate receptor activity in cultured human monocyte-derived macrophages. Blood, 1994. 84(8): p. 2452-6; Greenberg, S., et al., Extracellular nucleotides nzediate Ca2+ fluxes in. J774 macrophages by two distinct n2echanisnzs. J
Biol Chem, 1988. 263(21): p. 10337-43). This allows the testing for P2Z's influence by measuring the influx of molecules smaller than 0.9 kDa, to which the cell is normally not permeable. Propidium iodide (PI) (0.414 kDa) and lucifer yellow (LY) (0.46 kDa) should be allowed through if P2Z is activated, and trypan blue (TB) (0.96 kDa) should be excluded under all circumstances unless necrosis has occurred (Di Virgilio, F., The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death.
Imn.iunol Today, 1995. 16(11): p. 524-8; Coutinho-Silva, R. and P.M.
Persechini, P2Z
purinoceptor-associated pores induced by extracellular ATP in inacrophages and cells. Am J Physiol, 1997. 273(6 Pt 1): p. C1793-800; Steinberg, T.H., et al., pe>^meabilizes the plasma zzzeznbrane of mouse macrophages to fluorescent dyes. J Biol Chem, 1987. 262(18): p. 8884-8). The same conditions used in the previous experiment were repeated to observe and measure the entry of propidium iodide or trypan blue in J774A1 cells. Thus P2Z influence would be characterized by cells that were PI
and LY
positive but TB negative.
Using flow cytometry, cells incubated with anti-RTF + 0.75mM ATP had pronounced channel formation judging from their incorporation of PI (Figure 6). This was confirmed by immunofluorescence microscopy (Figure 6). Cells reacted with anti-RTF and 0.75mM ATP together were found to be permeable to PI, but not to trypan blue (Figure 6). In contrast, control cells permeabilized with 70% ETOH were positive for both dyes (data not shown). Cells that were incubated with anti-RTF alone or 0.75mM ATP alone (Figure 6) showed no PI incorporation, while those incubated with both did incorporate PI. These results were confirmed using lucifer yellow (not shown).
This demonstrates that anti-RTF and ATP togetlier can induce the opening of channels >0.9 kDa, and yet shows membrane integrity is still intact.
Example 12: RTF regulates IL-1(3 secretion To show that RTF regulates IL-1p secretion, THP-1 macrophages were incubated with both 1mM and 3mM ATP, or anti-RTF and assayed for IL-1(3 secretion by ELISA. Since anti-RTF abrogates RTF function, our hypothesis was that anti-RTF
would induce IL-(3 secretion, showing that RTF is a regulator for this molecule.
5x105 THP macrophage cells were stimulated with 5nghnl of LPS and 1x105 PBMC for 2.5 hours. These cells were then washed and iiicubated in a final concentration of either 0 ATP, 3mM ATP, 1mM ATP, or anti-RTF for a period of 3 hours. The supernatants were assayed for IL-1(3 by ELISA (R&D systems). pg IL-1(3 per well was calculated from the optical densities. Results are expressed as the mean of 3 independent experiments.
As shown in Figure 7, cells incubated with media alone, secreted 61+1-14 pg IL-1 j3, forming the baseli.ne. Cells incubated with 3mM ATP secreted 285+/-25 pg (78+/-5.1% above baseline). Cells incubated with 1.mM ATP secreted 130+/-44 pg IL-1(3 (49+/-5.6 above baseline). Ce1Ls incubated with anti-RTF alone secreted 114 +/-22 pg IIrl (3 (an increase 47+1-3.5%), about the equivalent of cells incubated with 1mM ATP.
This shows that anti-RTF alone can induce secretion, suggesting that RTF is a regulator oflL-1(i.
Example 13: Anti-RTF is-cytotoxic to ovarian carcinoma cell A2780 ovarian carcinoma cells were grown in 96 well plates until 100%
confluent. Wells were identified, and cells were then incubated with 3mM ATP, 6mM
ATP, 20 g of anti-RTF and 20 ug of anti-RTF combined with 3mM ATP and 6mM
ATP. Cells were incubated for 18 hours at 37 C in a 5% CO 2 environment. Cells were then harvested and assayed using flow cytometry for Caspase 3 activation as an indicator for cell death. As shown in Figure 8, anti-RTF is significantly more cytotoxic then extracellular ATP at the indicated concentrations. Addition of extracellular ATP
did not significantly enhance cytotoxicity.
Example 14. In vivo effect of anti-RTF
Female athymic nude mice purchased from Harlan Sprague Dawley approximately 11 weeks old. All mice were injected with 200 1 of a 1:1 slurry of a MATRIGELTM mix containing 5x 106 A2780 ovarian carcinoma cells. Tumor cells were transplanted subcutaneously in the upper flank of the right leg. Two mice were untreated and kept as a control to measure tumor growth. The remaining six mice were injected with anti RTF antibody. All mice were left untreated for I week in order for a tumor and its vascular bed to become established. On the eighth day all mice that were treated were injected with 100ug of anti RTF antibody in a volume of 100 1 of PBS.
Injections were given in the tumor bearing flank of the animal. Antibody was not injected directly into the tumor, but was injected into the area of the tumor bed. Mice received 300 g of antibody per week using a 28 gage needle. Mice were injected every Sunday, Tuesday and Friday. Injections took place over 5 weeks. The experiment was terminated when the control mice tumor burden became too obstructive for mice to ambulate.
The median tumor volume of the control animals after 5 weeks without anti-RTF
treatment was 8448 mm3 . The median tumor volume for the anti-RTF treated animals(n=6) was 364 mm3. In two of the treated animals no measurable tuinor was observed (tumor volume range 0-1670). These results clearly indicate the possible usefiilness of the antibody and or the inhibition of the RTF associated ATPase complex in tumor therapy It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art.
Such changes and modifications can be made witliout departing fiom the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims (2)
1. The use of an anti-Regeneration and Tolerance Factor (RTF) antibody for inducing apoptosis in an ovarian carcinoma cell.
2. The use of claim 1 wherein the antibody is a monoclonal antibody or a polyclonal antibody.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44649903P | 2003-02-10 | 2003-02-10 | |
US60/446,499 | 2003-02-10 | ||
US10/774,708 | 2004-02-09 | ||
US10/774,708 US7211257B2 (en) | 2003-02-10 | 2004-02-09 | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody |
PCT/US2004/003969 WO2004071441A2 (en) | 2003-02-10 | 2004-02-10 | Compositions and methods to modulate immune and inflammatory responses |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2515366A1 CA2515366A1 (en) | 2004-08-26 |
CA2515366C true CA2515366C (en) | 2010-04-20 |
Family
ID=32871987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2515366A Expired - Fee Related CA2515366C (en) | 2003-02-10 | 2004-02-10 | Compositions and methods to modulate immune and inflammatory responses |
Country Status (4)
Country | Link |
---|---|
US (1) | US7211257B2 (en) |
EP (1) | EP1596811A4 (en) |
CA (1) | CA2515366C (en) |
WO (1) | WO2004071441A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8138160B2 (en) | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196526A (en) | 1989-11-28 | 1993-03-23 | University Of Health Sciences/The Chicago Medical School | CDNA clone for T-cell suppressor inducer factor |
EP0760850A1 (en) | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
NZ502568A (en) | 1997-08-05 | 2003-01-31 | Stressgen Biotechnologies Corp | Compositions to enhance immune responses against HPV (human papilloma virus) protein antigens and against tumours exhibiting an HPV protein antigen |
-
2004
- 2004-02-09 US US10/774,708 patent/US7211257B2/en not_active Expired - Fee Related
- 2004-02-10 WO PCT/US2004/003969 patent/WO2004071441A2/en active Application Filing
- 2004-02-10 EP EP04709875A patent/EP1596811A4/en not_active Withdrawn
- 2004-02-10 CA CA2515366A patent/CA2515366C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2004071441A3 (en) | 2006-01-05 |
CA2515366A1 (en) | 2004-08-26 |
US7211257B2 (en) | 2007-05-01 |
EP1596811A4 (en) | 2007-10-03 |
WO2004071441A2 (en) | 2004-08-26 |
EP1596811A2 (en) | 2005-11-23 |
US20040219145A1 (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Inflammation: a novel therapeutic target/direction in atherosclerosis | |
JP2022081543A (en) | Anti-trem2 antibodies and methods of use thereof | |
JP5164167B2 (en) | Agonists, antagonists and immunotoxins of immunoregulatory tumor necrosis factor receptor 25 (TNFR25) | |
ES2328597T3 (en) | MODULATION OF NKG2D. | |
JP5569946B2 (en) | Immunosuppressants and preventive and therapeutic agents for autoimmune diseases | |
US11485787B2 (en) | Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof | |
TW201934552A (en) | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | |
US11352400B2 (en) | PI3K gamma inhibitor peptide for treatment of respiratory system diseases | |
CN111032658B (en) | 5-5 fused rings as C5a inhibitors | |
WO2014058915A2 (en) | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis | |
WO2020227159A2 (en) | Methods of modulating immune activity | |
TW201900212A (en) | Method for treating immune-related adverse events in cancer therapy using soluble CD24 | |
US20130011835A1 (en) | Compositions and methods for treating inflammation | |
US10975144B2 (en) | CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibody | |
Ko et al. | A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor | |
KR20210053306A (en) | Combination therapy with a C-C chemokine receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors | |
US9428568B2 (en) | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | |
JP6151692B2 (en) | Methods and compositions for modulating voltage-gated calcium channel function | |
CA2515366C (en) | Compositions and methods to modulate immune and inflammatory responses | |
WO2011000384A1 (en) | Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms | |
WO2008055889A1 (en) | Compositions and methods of treating oncological, inflammatory and autoimmune diseases mediated by sema4a | |
US7943130B2 (en) | Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation | |
Park et al. | Activation of formyl peptide receptor 1 elicits therapeutic effects against collagen‐induced arthritis | |
EP3538550A1 (en) | Or10h1 modulators and uses thereof | |
US20230128075A1 (en) | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130211 |